QuantiVirus™ HPV E6/E7 mRNA test for Cervical Cancer

QuantiVirus™ HPV E6/E7 mRNA test for Cervical Cancer

Cat# DC-01-0001

Size : 96Reactions

Brand : DiaCarta

Contact local distributor :


Phone : +1 850 650 7790

QuantiVirus™

HPV E6/E7 mRNA Test for Cervical Cancer

Detects the presence of HPV E6/E7 mRNA for early detection of cervical cancer.

R

CE/IVD Marked Product

R

Research Product

R

Research Service

Get a Quote

Early Detection/Screening

Diagnosis

Therapy Selection

Therapy Monitoring

HPV Test

Almost all cervical cancer cases are caused by persistent HPV infection. HPV testing provides better sensitivity than cytology alone and allows earlier detection of cervical cancer. New American Cancer Society guideline (2020) recommends HPV testing every five years as a preferred screening method for cervical cancer.

Get a Quote

The HPV mRNA assays provide higher specificity than HPV DNA-based assays. The improved specificity helps reduce the number of people sent to colposcopy and prevent over treatment.

Efficient Workflow: direct approach without DNA/RNA purification, RT-PCR, or target RNA amplification

Accepted sample type: cervical samples (PreservCyt® and SurePath® preservation fluid) and FFPE

The test differentiates between persistent and transient HPV infection

The DiaCarta Offerings

PRODUCT

QuantiVirus™ HPV mRNA Test is a CE/IVD marked product for countries with CE/IVD compliance. It could also be used as a research product in the United States.

  • Pack size: 96 reactions per kit
  • Catalog #: DC-01-0001 (CE/IVD version)
  • Catalog #: DC-01-0001R (Research Use Only version)
Get a Quote

SERVICE

QuantiVirus™ HPV E6/E7 mRNA Test is available at DiaCarta as a research service. 

Get a Quote

Why do we test HPV mRNA?

FDA approves both HPV DNA and mRNA testing methods for HPV testing.

Get a Quote

HPV DNA Test

HPV DNA testing detects DNA present in transient infection (HPV cleared within a couple of years) and persistent infection.

Suboptimal specificity

Although HPV DNA testing is widely used for HPV testing, it suffers from suboptimal specificity, leading to many unnecessary colposcopy and follow-up procedures.

False-negative detection

In more severe cervical intraepithelial lesion (CIN) cases, HPV DNA is decreased while HPV mRNA is increased. This leads to false-negative detection using the HPV DNA test.

HPV mRNA Test

HPV mRNA test detects mRNA in infected cells, where E6/E7 mRNA is produced and eventually changes the normal cells to cancer cells.

Higher specificity

The HPV mRNA assays provide higher specificity than HPV DNA-based assays. The improved specificity helps reduce the number of people sent to colposcopy and prevent over treatment.

Resources

You might also be interested by the following products:



Cat#
Description
Cond.
Price Bef. VAT